HB-0043

N/A

Report date: 2026/03/27 20:01:50

Base Information

Drug NameHB-0043
Drug Alias NameHB-0043
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-36 receptor modulatorsInterleukin-17 modulators
TargetsInterleukin-36 receptorInterleukin-17
Therapy Area/IndicationsAutoimmune DiseasesPsoriasisAcne Vulgaris +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHuaBo Biopharm Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesPsoriasisAcne Vulgaris +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A